We are live on ! Find out more
MP

MFN Partners Portfolio holdings

AUM $4.77B
1-Year Est. Return 72.29%
This Fund
S&P 500
This Quarter Est. Return
+4.7%
1 Year Est. Return
+72.29%
3 Year Est. Return
+200.41%
5 Year Est. Return
+244.77%
10 Year Est. Return
–
AUM
$630M
AUM Growth
+$9.97M
Cap. Flow
-$1.98M
Cap. Flow %
-0.31%
Top 10 Hldgs %
91.03%
Holding
18
New
3
Increased
3
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$34.6M
2
CYCN icon
Cyclerion Therapeutics
CYCN
+$21.1M
3
LBTYK icon
Liberty Global Class C
LBTYK
+$16.1M
4
GTT
GTT Communications, Inc.
GTT
+$7.73M
5
XPO icon
XPO
XPO
+$4.03M

Top Sells

Rank Stock Value
1
PCG icon
PG&E
PCG
+$24.1M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$10.7M
3
NAVI icon
Navient
NAVI
+$5.29M

Sector Composition

Rank Sector Weight
1 Healthcare 38.31%
2 Communication Services 19.91%
3 Energy 13.03%
4 Utilities 10.19%
5 Financials 10.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$151M 23.92%
900,101
+250,000
+38% +$34.6M
FOXA icon
2
Fox Class A
FOXA
$24.8B
$86.8M 13.78%
2,369,331
– –
PCG icon
3
PG&E
PCG
$39B
$64.2M 10.19%
2,800,000
-1,200,000
-30% -$24.1M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$586M
$54M 8.58%
4,939,541
-958,271
-16% -$10.7M
XPO icon
5
XPO
XPO
$23.4B
$52.8M 8.39%
2,642,546
+197,872
+8% +$4.03M
LNG icon
6
Cheniere Energy
LNG
$54.2B
$51.3M 8.15%
750,000
– –
GS icon
7
Goldman Sachs
GS
$289B
$35.6M 5.65%
173,811
– –
PXD
8
DELISTED
Pioneer Natural Resource Co.
PXD
$30.8M 4.88%
200,000
– –
FG
9
DELISTED
FGL Holdings Ordinary Shares
FG
$25.2M 4%
3,000,000
– –
GTT
10
DELISTED
GTT Communications, Inc.
GTT
$22M 3.49%
1,250,000
+250,000
+25% +$7.73M
CYCN icon
11
Cyclerion Therapeutics
CYCN
$15.2M
$17M 2.7%
+74,394
New +$21.1M
LBTYK icon
12
Liberty Global Class C
LBTYK
$3.5B
$16.6M 2.63%
+625,558
New +$16.1M
TAK icon
13
Takeda Pharmaceutical
TAK
$56.7B
$13.9M 2.21%
785,000
– –
NAVI icon
14
Navient
NAVI
$819M
$3.33M 0.53%
244,300
-405,700
-62% -$5.29M
ACRS icon
15
Aclaris Therapeutics
ACRS
$715M
$3.29M 0.52%
1,500,000
– –
EOLS icon
16
Evolus
EOLS
$397M
$1.75M 0.28%
+120,000
New +$2.38M
RVNC
17
DELISTED
Revance Therapeutics, Inc.
RVNC
$597K 0.09%
46,000
– –
BMY icon
18
CALL
Bristol-Myers Squibb
BMY
$129B
– –
-1,000,000
Closed -$47.7M

Similar funds

WAM
WT Asset Management Hong Kong $4.77B AUM 334.05% 1-Year Est. Return
MF
Milford Funds Auckland $4.77B AUM
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $4.76B AUM 10.22% 1-Year Est. Return
GAM
Generali Asset Management Trieste, Italy $4.79B AUM 26.21% 1-Year Est. Return
Twin Tree Management
Twin Tree Management Dallas, Texas $4.75B AUM 58.16% 1-Year Est. Return
JCM
Junto Capital Management New York $4.74B AUM 27.96% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return

MFN Partners's Q2 2019 Portfolio in Review

As of Q2 2019, MFN Partners held 18 positions worth $630M, up 1.6% from $620M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

MFN Partners's Q2 2019 filing shows 3 new, 3 increased, 3 reduced and 1 closed positions. Its largest new stake was Cyclerion Therapeutics: 74,394 shares worth $17M. The largest sale was PG&E, an estimated $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 30% a quarter earlier, followed by Communication Services and Energy.

  • MFN Partners's largest Q2 2019 buy was Cyclerion Therapeutics: 74,394 shares worth $17M.
  • MFN Partners added most to Allergan plc in Q2 2019, an estimated $34.6M increase.
  • MFN Partners's biggest Q2 2019 reduction was PG&E, cutting an estimated $24.1M.
  • MFN Partners's ten largest holdings make up 91% of its $630M portfolio in Q2 2019.
  • MFN Partners opened 3 new positions and closed 1 in Q2 2019.
  • MFN Partners's portfolio value rose 1.6% quarter-over-quarter to $630M.

Based on MFN Partners's 13F filing for Q2 2019, filed 14 Aug 2019.